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Abstract
Background: It is becoming increasingly accepted that a shift is needed from the traditional target-
based approach of drug development towards an integrated perspective of drug action in
biochemical systems. To make this change possible, the interaction networks connecting drug
targets to all components of biological systems must be identified and characterized.
Results:  We here present an integrative analysis of the interactions between drugs and
metabolism by introducing the concept of metabolic drug scope. The metabolic drug scope
represents the full set of metabolic compounds and reactions that are potentially affected by a drug.
We constructed and analyzed the scopes of all US approved drugs having metabolic targets. Our
analysis shows that the distribution of metabolic drug scopes is highly uneven, and that drugs can
be classified into several categories based on their scopes. Some of them have small scopes
corresponding to localized action, while others have large scopes corresponding to potential large-
scale systemic action. These groups are well conserved throughout different topologies of the
underlying metabolic network. They can furthermore be associated to specific drug therapeutic
properties.
Conclusion:  These findings demonstrate the relevance of metabolic drug scopes to the
characterization of drug-metabolism interactions and to understanding the mechanisms of drug
action in a system-wide context.
Background
There is a growing perception that the traditional
approach for drug development has not been as effective
as could be expected [1]. Although investments by phar-
maceutical companies have been growing continuously in
the last decades, the number of newly approved drugs has
not followed the same trend [2,3]. Currently the main
trend in drug design and development follows the target-
based approach. The drug target is generally a single gene
or gene product which has been clearly identified as hav-
ing an action on the disease. Disease treatment seeks to
modulate this action without affecting other processes in
the organism. However, many diseases are multifactorial,
and the current approach fails to take such systemic
aspects into account [4-6]. The complex interactions
between numerous molecular processes and pathways
involved in diseases imply that any treatment targeting a
local element will create secondary effects on the entire
system. The lack of an integrative investigation of drug
action can lead to either positive or negative systemic
effects being missed. In the first case, the treatment only
provides limited and localized cure for the disease while
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failing to address large-scale causes. In the second case,
new drugs are developed with harmful side effects that are
only revealed at a late stage of clinical studies. This prob-
lem of drug attrition is a major concern for the pharma-
ceutical industry and an important source of financial
costs. Additional problems can be caused by side-effects
resulting from combinations of several drugs, arising from
unexpected interactions which were not revealed by local
analysis.
To increase the productivity of drug development and the
efficiency of new drugs, there is thus a strong need to
move beyond the investigation of drug action from the
point of view of direct targets only, and to take into
account the full network of interactions connecting the
targets with the rest of the system. Drug development
needs to be approached not only in terms of a molecular
biology process, but also as a systems biology process [7-
10]. This awareness has recently led to the completion of
major studies revealing the large-scale interactions
between drugs, drug targets and diseases from a network-
based perspective [11-15]. However, these approaches did
not unveil yet how specific drugs interact in biochemical
systems, and new methods are needed to gain an inte-
grated perspective of the mechanisms of drug action in
complex systems.
To this aim, we here introduce a new view of drug-metab-
olism interactions based on the concept of metabolic drug
scope. The concept of a scope was previously developed in
metabolic networks [16]. It uses an expansion process
based on the principle that, for any reaction to take place,
all necessary substrates must be present and the products
of these reactions may in turn be used by other reactions.
Starting from a set of seed compounds, reactions whose
substrates are available in the seed set are iteratively
added, resulting in the generation of a series of expanding
networks. When no further reaction can be added, the
final network obtained is defined as the scope of the seeds.
The scope represents the set of all compounds that can in
principle be synthesized from the seeds. The properties of
scopes in metabolic networks have been described in great
detail [17-19]. This concept was already proven valuable
in revealing features of the evolution of metabolic sys-
tems, leading notably to demonstrating how the shift
from anoxic to oxic environments transformed the archi-
tecture of metabolic networks and how the availability of
oxygen allowed an increase in biological complexity [20].
Recently, it was shown that features of scopes could also
be linked to chemical structures and biological functions
of the seeds [21].
We here extend the scope paradigm to drug-metabolism
interactions. Many drugs target genes or gene products
that are involved in metabolic functions. When a meta-
bolic reaction is targeted by a drug, the concentrations of
its substrates and products are affected as a result of drug
action. Other reactions which use the products of the ini-
tial reactions are in turn affected by these perturbations.
By iterative expansion, the entire scope of the initial sub-
strates and products can in principle be affected by the
drug. Basing on this principle, we thus introduce the con-
cept of a metabolic drug scope defined by the following: the
scope of a drug is the scope resulting from the expansion
of a set of seed compounds containing the substrates and
products of all metabolic reactions targeted by that drug.
The metabolic drug scope essentially represents the largest
network of possible action of a drug in a metabolic sys-
tem. In the following sections, we show how metabolic
drug scopes reveal new features of the systemic modes of
drug action through a detailed analysis of the scopes of
276 human approved drugs from the DrugBank database
[22] having metabolic targets. As scopes depend on the
topology of the metabolic network used in the expansion
process, we analyzed the action of each drug in four differ-
ent systems: a human vs. a reference metabolic network
consisting of the union of all organisms, and for each of
those a reversible vs. an irreversible topology. Further
details on the construction of metabolic drug scopes are
provided in the Methods section. Our results show that
the distribution of scopes is highly uneven and that they
can be classified into different categories. Some drugs
have small scopes associated to localized action, while
others have large scopes associated to potential wide-
spread systemic action. These classes are relatively well
conserved throughout the four systems. A network of met-
abolic drug scopes, where scopes are connected when
their Jaccard distance is smaller than a given threshold,
confirms these characteristics, and a k-core decomposi-
tion algorithm reveals several highly connected central
components as well as peripheral subgraphs. We subse-
quently analyzed the correlations between metabolic drug
scopes and therapeutic properties of drugs, and show that
therapies are not distributed uniformly but can often asso-
ciated to specific groups of scopes, correlated to similar k-
cores. Metabolic drug scopes therefore offer a new avenue
to analyze drug-metabolism interactions and may provide
valuable assistance to the drug development and assess-
ment process.
Results
Metabolic drug scopes are highly uneven
The first step in characterizing the properties of metabolic
drug scopes consisted in analyzing the distribution of
their sizes. In many cases multiple drugs have the same
targets and these drugs automatically have the same
scope. To avoid identical scopes to be counted several
times, we beforehand selected a subset of scopes where
only one representative of each group of identical scopesBMC Chemical Biology 2009, 9:4 http://www.biomedcentral.com/1472-6769/9/4
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was kept, resulting in a group of 97 scopes which are all
different. The distributions of sizes of these scopes are
shown in Figure 1 for each of the four metabolic networks.
Histograms reveal a highly heterogeneous distribution.
Scope sizes are not distributed evenly, nor do they show
any kind of regular distribution law. On the contrary, sizes
are often concentrated around particular values: for exam-
ple, in the reference reversible network there are 48 scopes
of size comprised between 1920 and 1940. The presence
of such peaks can be attributed to particular metabolites.
It is known that the inclusion of ubiquitous metabolites
has a strong influence on the size of scopes [23]. The most
frequent of them is ATP, which together with water and
Distribution of scope sizes Figure 1
Distribution of scope sizes. Multiple identical scopes are counted only once. The width of intervals is 20 for reference net-
works (top), 5 for human networks (bottom).BMC Chemical Biology 2009, 9:4 http://www.biomedcentral.com/1472-6769/9/4
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oxygen generate a scope of 1929 compounds. The previ-
ously mentioned peak is thus clearly attributable to the
presence of ATP. Nevertheless, it is remarkable that scopes
do not exhibit larger variations around peaks. This obser-
vation suggests that metabolic drug scopes can be sepa-
rated into distinct and relatively homogeneous groups,
where internal variations are small.
We analyzed the distribution of scope sizes with regard to
the total number of targets of each drug, including non-
metabolic targets, in the four metabolic networks (Addi-
tional File 1). The distribution shows that there is no sig-
nificant correlation between these two variables
(correlation coefficients between 0.15 and 0.19). This
observation confirms that scopes are more dependent on
the presence of particular metabolites than on the number
of targets.
The frequencies of occurrence of chemical compounds
and reactions in metabolic drug scopes are plotted in Fig-
ures 2 and 3 respectively. These distributions are very
irregular and do not follow any classical law either. Peaks
can be observed at some values, separated by intervals of
zero frequency. Such distributions can be explained by the
fact that scopes tend to grow through the incorporation of
groups of metabolites, ubiquitous metabolites bringing
large numbers of other metabolites with them. The sharp
peaks observed at some high values, particularly for the
reference network, are a further indication that groups of
very similar scopes exist. Each of these peaks corresponds
to a group of scopes containing many of the same com-
pounds and reactions. It was thus desirable to use cluster-
ing methods to reveal such groups of drugs.
Scopes reveal four main categories of systemic drug action
We clustered metabolic drug scopes using the Jaccard dis-
tance as a measure of dissimilarity between scopes (see
Methods). In the reference reversible network, four clus-
ters of metabolic drug scopes were obtained, whose main
properties are listed in Table 1. In order to highlight the
main features and differences between these clusters, we
constructed the consensus scope of each cluster. The consen-
sus scope is the set of compounds present in at least 50%
of all scopes of a cluster (see Methods). Consensus scopes
of the four clusters are plotted over a genome scale meta-
bolic map in Figure 4.
Clear differences can be observed between these four drug
clusters. Cluster I is composed of drugs whose scope is
very small. These scopes only slightly differ from the min-
imal scope induced by water and oxygen alone. When
only water and oxygen are used as seeds and cofactors are
allowed, a minimal scope of 12 compounds is obtained.
The average size of scopes in cluster I is 15, and the size of
their consensus scope is 12. These scopes thus mainly con-
sist of the minimal scope with the addition of a handful
of other compounds. These additional compounds are
isolated and poorly connected to the rest of the metabolic
network, as they do not further increase the size of the
scope. Drugs belonging to cluster I are therefore only able
to affect a limited and specific part the metabolic network.
Their action is not allowed to propagate beyond the
intended target and should be mainly local.
Cluster III contains the same minimal component
induced by water and oxygen, but additionally contains a
larger component centered on arachidonic acid metabo-
lism. This component, which can be seen at the left-hand
side of the genome scale metabolic map (Figure 4), is
absent from the three other clusters. Interactions of cer-
tain drugs with arachidonate metabolism have long been
known and this pathway is particularly important in anti-
inflammatory treatments [24,25].
Clusters II and IV on the contrary contain large scopes
spreading through many parts of the metabolic network.
Drugs belonging to these clusters can therefore in princi-
ple affect a wide area of metabolism and potentially have
widespread systemic effects. Such dramatic increase in the
size of scopes can be achieved by the inclusion of particu-
lar metabolites. For example, Raymond and Segrè [20]
showed that the availability of oxygen leads to a major
expansion of the size and complexity of metabolic sys-
tems. Although oxygen and water where assumed to be
always available in our analysis, similar increases can be
achieved by the inclusion of other metabolites. The most
important of them is ATP, which explains the distinction
between cluster II and IV: ATP is present in all scopes of
cluster II but absent from the scopes of cluster IV. It is
worth noticing that ATP does not have the largest scope of
all metabolites though: this position is held by adenosine
5'-phosphosulfate [23], which is only present in a small
number of scopes of cluster II (16 out of 163). The size of
a compound's scope alone is thus not a determining factor
for its recurrent occurrence in metabolic drug scopes.
Pyruvate plays a major role too in separating different
clusters, as it is present in clusters II and IV, but absent
from clusters I and III.
Drug categories are conserved in different networks
The scope construction process fundamentally depends
on the topology of the underlying metabolic network. We
therefore conducted the same analysis in four different
networks: a reference network consisting of the union of
all organisms vs. a human metabolic network, and in each
of those a reversible vs. an irreversible topology (see Meth-
ods). Clustering of metabolic drug scopes in these other
networks resulted in more clusters being found than in
the reference reversible network (Tables 2, 3, 4). However,
most of these new clusters are very small, containing onlyBMC Chemical Biology 2009, 9:4 http://www.biomedcentral.com/1472-6769/9/4
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in a handful of drugs. They would fall into one of the four
main clusters if the cutoff were increased. The detailed
composition of clusters is provided for the four networks
in Additional File 2.
The four main clusters are still present and exhibit similar
characteristics as in the reference reversible network.
Although the average size of scopes is smaller in irreversi-
ble and human networks than in the reference reversible
case (which is natural because scopes in irreversible and
human networks are necessarily subsets of scopes in the
reference reversible network), it is worth noticing that the
consensus scopes of the four main clusters remain very
similar to their reference reversible counterparts (Figures
Frequencies of occurrence of compounds in scopes Figure 2
Frequencies of occurrence of compounds in scopes. Multiple identical scopes are counted only once. The width of 
intervals is 2.BMC Chemical Biology 2009, 9:4 http://www.biomedcentral.com/1472-6769/9/4
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2, 3, 4). Overlaps between consensus scopes from differ-
ent clusters were made apparent by Venn diagrams (Figure
5). Groups consisting of large (II and IV) and small scopes
(I and III) are clearly distinguishable in the reference
reversible network. In the reference irreversible network,
this pattern is well conserved despite additional small
clusters appearing. In human networks, more complex
overlapping patterns emerge but two groups of large
scopes are still present.
More significantly, the drug composition of the four main
clusters is well conserved throughout the different net-
works (Figure 6). Cluster III is even 100% conserved in all
four networks. The only significant difference appears
Frequencies of occurrence of reactions in scopes Figure 3
Frequencies of occurrence of reactions in scopes. Multiple identical scopes are counted only once. The width of inter-
vals is 2.BMC Chemical Biology 2009, 9:4 http://www.biomedcentral.com/1472-6769/9/4
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with cluster IV, which is less conserved in the human irre-
versible network. The latter network is the less densely
connected of all four, therefore emphasizing the depend-
ence of metabolic drug scopes on local targets and leading
to a higher scattering of scopes. Table 4 shows that this
network has a large number of very small clusters, making
it more difficult to identify large groups of drugs with
common properties as a result. On the other side, this net-
work is the most appropriate when it comes to identifying
highly specific drug-metabolism interactions, as scopes
tend to be more restricted to the immediate neighbor-
hood of drug targets.
Metabolic drug scopes are correlated to therapeutic 
properties
As metabolic drug scopes are related to features of the sys-
temic modes of drug action, a fundamental question was
to determine whether the properties of metabolic drug
scopes could be linked to therapeutic properties of the
drugs themselves. We consequently analyzed the distribu-
tion of therapeutic properties, defined by level 1 tags of
the ATC classification (see Methods), in the four main
groups of drugs identified by clustering of their scopes. As
shown in Figure 7, the repartition of therapies is not uni-
form in the four groups. While clusters II and IV show rel-
atively similar compositions in therapies, they together
strongly differ from clusters I and III. 55% of drugs in clus-
ter III belong to the musculo-skeletal system (M) category,
and 77% of all class M drugs belong to cluster III. The
enrichment of class M in cluster III is statistically highly
significant (p-value = 10-21). Cluster I is dominated by
antiinfectives (J; p = 3·10-4) and sensory organs drugs (S;
p = 0.021); it contains half of all blood related drugs (B; p
= 0.009) and three quarters of hormonal preparations (H;
p = 0.002). Clusters II on the contrary is dominated by car-
diovascular drugs (C; p  = 0.039), this class is almost
absent from cluster I and III.
The fact that clusters II and IV show more similarities than
the other clusters must be put into relation with the fact
that these two clusters correspond to large scopes, while
clusters I and III correspond to small specific scopes.
Therefore, there appears to be a relationship between the
composition and extent of a metabolic drug scope and its
therapeutic properties. This observation reinforces the
potential role of scopes as an indicator of drug action and
effects in a systems-wide context.
A complementary analysis of the relationships between
metabolic drug scopes and therapies was realized by con-
structing a network of scopes (see Methods). Complex
interwoven interactions can be analyzed in networks by
identifying the cohesive building blocks of the system.
Cohesive subgraphs are sets of nodes with high density of
edges in their network neighborhood. We applied an iter-
ative decomposition method to uncover k-core subnet-
works, defined as the largest subgraphs where every node
has at least degree k. Figure 8 shows the decomposition of
a network of metabolic drug scopes, for a threshold of 0.2
in the Jaccard distance between scopes and in the human
irreversible case. Each colored node represents a different
core partition. Highly connected drugs are located in
innermost cores where overlapping with complete ther-
apy graphs is more evident. The overlapping of therapy
cliques with k-core subgraphs confirms links between the
composition of scopes and the effects of drugs.
Discussion
It is a widely accepted fact that new approaches are needed
to facilitate and increase the quality of the drug target
identification and drug development processes. High lev-
els of investment by pharmaceutical companies in recent
years have not been followed by a corresponding increase
in discovery and commercialization of new drugs, and the
traditional reductionist approach of drug development is
seen as a possible cause for this lack of success. Many dis-
eases are multifactorial and can not be handled by target-
ing only isolated molecules, but systemic aspects need to
be taken into account. The toxicity and harmful side-
effects of some drugs can also be accounted to by a failure
of considering drug action in an integrated and systemic
way. When a molecular target is perturbed by a drug,
effects are not limited to that target but potentially extent
to the whole interaction network connected to it. It there-
fore becomes more and more necessary to study drug
action with a systems biology perspective, and important
efforts are needed to construct and characterize the inter-
action networks connecting drug targets to all compo-
nents of a biological system.
Table 1: Clusters of metabolic drug scopes in the reference reversible network.
Cluster Id Number of drugs in cluster Average scope size Significant compounds in consensus scope
I3 7 1 5 -
II 163 1963 ATP, NAD+, Pyruvate, Galactose
III 35 69 Arachidonate
IV 41 995 Pyruvate, GalactoseBMC Chemical Biology 2009, 9:4 http://www.biomedcentral.com/1472-6769/9/4
Page 8 of 14
(page number not for citation purposes)
Consensus scopes of drug groups plotted over a Kegg Atlas genome scale metabolic map for the reference reversible meta- bolic network Figure 4
Consensus scopes of drug groups plotted over a Kegg Atlas genome scale metabolic map for the reference 
reversible metabolic network. Chemical compounds belonging to the scope appear as red dots.BMC Chemical Biology 2009, 9:4 http://www.biomedcentral.com/1472-6769/9/4
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The metabolic network is one of these interaction net-
works, and metabolic drug scopes provide a straightfor-
ward and efficient tool to construct them and to analyze
their properties. We have shown that metabolic drug
scopes can vary greatly in size and distribution. When a
drug has a small scope, its action is necessarily restricted
to a small set of reactions and compounds. Whether this
feature should be considered as enviable or not is open to
discussion, and most certainly depends on the context.
When a disease is due to the malfunction of a specific
process or the lack of a specific metabolic compound, a
small scope would a priori be preferable, since it guaran-
tees that no harmful side-effects are induced by the drug.
Large scopes are more difficult to assess: on the one side,
a drug with a large scope is potentially more efficient in
combating a multifactorial disease, as its effects can
extend far beyond the immediate targets. On the other
side, because it is difficult so far to quantify such large-
scale effects, it cannot be excluded that they might include
negative consequences for the organism. A wishful goal
for the future should therefore involve moving beyond
this type of qualitative view of drug-metabolism interac-
tions towards a more quantitative view. For example,
being able to predict which reactions and compounds of
the metabolic drug scope are enhanced or repressed by the
drug's action could lead to a whole new level of knowl-
edge.
It is also remarkable that correlations can be observed
between metabolic drug scopes and therapeutic properties
of drugs. This observation strengthens the relevance of
metabolic drug scopes in studying a drug's action and
effects in a systems-wide context. As they discriminate the
networks of action of different drugs, scopes also offer dis-
crimination between the consequences of these actions.
Whether this finding can be turned into a predictive tool,
i.e. to determine scopes and drug targets with the aim of
obtaining a desired effect, remains open to investigation
but certainly represents a promising perspective.
Conclusion
Metabolic drug scopes provide a new perspective on inter-
actions between drugs and metabolic systems going
beyond more traditional network-based approaches. This
analysis constitutes a first step in the integration between
drug-target interaction networks on the one side, and sto-
ichiometric interactions in metabolic systems on the
other. In the future, such approaches will have to be
extended toward quantitative modeling, with the aim of
achieving a precise understanding of how drugs interact
Table 2: Clusters of metabolic drug scopes in the reference irreversible network.
Cluster Id Number of drugs in cluster Average scope size Significant compounds in consensus scope
I4 0 1 4 -
II 154 1606 ATP, NAD+, Pyruvate, Galactose
III 35 68 Arachidonate
IV 39 687 Pyruvate, Galactose
V1 2 7 C o A
VI 3 47 -
VII 3 35 -
VIII 1 38 -
Table 3: Clusters of metabolic drug scopes in the human reversible network.
Cluster Id Number of drugs in cluster Average scope size Significant compounds in consensus scope
I7 7 9 -
II 94 339 ATP, Pyruvate, Tyrosine, Galactose
III 35 40 Arachidonate
IV 30 130 Pyruvate
V 12 244 Pyruvate, Tyrosine, Galactose
VI 8 21 -
VII 1 44 Tryptophan, Tyrosine
VIII 4 11 -
IX 5 21 -
X3 2 2 -
XI 2 14 -
XII 2 11 -
XIII 1 30 -
XIV 1 33 Tyrosine
XV 1 16 -BMC Chemical Biology 2009, 9:4 http://www.biomedcentral.com/1472-6769/9/4
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with living systems. This knowledge will in turn enable us
to improve the drug development process and create more
efficient therapies based on optimized combinations of
multiple drugs.
Methods
Construction of metabolic drug scopes
The DrugBank database is a comprehensive bioinformat-
ics and chemoinformatics resource containing detailed
information about all US approved drugs and their
molecular targets [22]. We downloaded the database and
identified all drugs having enzymatic targets by extracting
their Enzyme Commission (EC) numbers. For each of
them, we compiled the list of substrates and products
using both the Kegg [26] and Brenda databases [27]. In
the case of unspecific reactions having multiple substrates
and products, we only selected the most common com-
pounds, as uncommon compounds are usually not sup-
ported by the scope construction application.
For each drug, the complete set of compounds deter-
mined in this way constituted the seeds of the metabolic
drug scope. Oxygen and water were added to the seeds if
not already present, as it is assumed that these com-
pounds are always available in a human metabolism con-
text. The following cofactors were also assumed to be
available for metabolic reactions, but they were not added
to the seeds: ATP, ADP, NAD, NADH, NADP, NADPH,
CoA. It is a recurrent question in metabolic network anal-
ysis to decide whether cofactors should be included or
not. We here included all of them because the fundamen-
tal basis of the metabolic scope is to encompass the largest
possible range of effects of a drug. Such effects can be
transmitted by cofactors as well as by other metabolites,
Table 4: Clusters of metabolic drug scopes in the human irreversible network.
Cluster Id Number of drugs in cluster Average scope size Significant compounds in consensus scope
I6 2 8 -
II 24 10 -
III 85 230 ATP, Pyruvate, Galactose
IV 35 40 Arachidonate
V1 4 1 1 -
VI 15 21 -
VII 13 27 -
VIII 5 110 Pyruvate
IX 8 21 -
X1 1 2 C o A
XI 1 25 CoA
XII 2 53 Tryptophan
XIII 3 21 -
XIV 2 14 -
XV 1 16 -
XVI 2 11 -
XVII 1 24 -
XVIII 1 30 Tyrosine
XIX 1 16 -
Venn diagrams showing overlapping between consensus scopes of clusters in each network Figure 5
Venn diagrams showing overlapping between consensus scopes of clusters in each network.BMC Chemical Biology 2009, 9:4 http://www.biomedcentral.com/1472-6769/9/4
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therefore the distinction would here appear rather artifi-
cial.
We subsequently used the MetaPath Online application
[19] to construct the scopes resulting from these seeds. For
each drug, we computed four different scopes based on
four metabolic networks: a reference network correspond-
ing to the union of all species vs. a human network, and
for each of those a reversible vs. an irreversible topology.
Scopes were saved as text files for subsequent analysis. The
full set of metabolic drug scopes for 276 drugs and 4 met-
abolic networks is provided in Additional File 3.
It frequently occurred that multiple drugs had the same set
of enzymatic targets. In this case the scopes of these drugs
are necessarily identical. In several parts of our analysis
such duplicate scopes were counted only once, so that we
used a subset of scopes that are all distinct. A list of drugs
and their enzymatic targets is provided in Additional File
4, where drugs with identical targets are highlighted in the
same color.
Clusters of metabolic drug scopes
We used the Jaccard distance between sets to define a
measure of dissimilarity between scopes. For two scopes A
and B, the Jaccard distance is 1 – |A∩B|/|A∪B|, where
|A∩B| is the number of compounds contained in the
intersection of A and B, and |A∪B| is the number of com-
pounds contained in the union of A and B. If two scopes
are identical their Jaccard distance is 0; if two scopes have
no compound in common their Jaccard distance is 1.
Venn diagrams showing overlapping between drugs belonging to the four main clusters in each network Figure 6
Venn diagrams showing overlapping between drugs belonging to the four main clusters in each network. (1) 
represents cluster I for all four networks. (2) represents cluster II for the reference reversible/irreversible and the human 
reversible networks, cluster III for the human irreversible network. (3) represents cluster III for the reference reversible/irre-
versible and the human reversible networks, cluster IV for the human irreversible network. (4) represents cluster IV for the 
reference reversible/irreversible and the human reversible networks, cluster V for the human irreversible network.
Top: Pie charts showing the distribution of therapeutic classes in the four main groups of drugs Figure 7
Top: Pie charts showing the distribution of therapeutic classes in the four main groups of drugs. Bottom: Repar-
tition of each therapeutic class through the four groups. Colors correspond to identifiers I to IV as indicated below the large 
pie charts.BMC Chemical Biology 2009, 9:4 http://www.biomedcentral.com/1472-6769/9/4
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Hierarchical clustering of metabolic drug scopes was cal-
culated with the R statistical computing environment
using the Jaccard distance as a measure of dissimilarity. At
first, each observation is a small cluster by itself. Clusters
are merged until only one large cluster remains which
contains all the objects. At each stage the two nearest clus-
ters are combined to form one larger cluster. We adopted
the complete linkage method, where the distance between
two clusters is computed as the distance between the two
farthest objects in the two clusters. This method tends to
keep outliers out of clusters and guarantees that all objects
inside clusters have strongly similar characteristics. A cut-
off value of 0.5 was used to define clusters, which was set
by observing the clustering tree and chosen to be robust
against variations.
Consensus scopes
Following a definition set by Matthäus et al. [21], the con-
sensus scope of a cluster is the set of compounds that are
contained in at least 50% of all scopes in the cluster. Con-
sensus scopes are useful to visualize the typical properties
of a group of metabolic drug scopes. Although the thresh-
old of 50% is arbitrary, this definition is very robust
against variations of the threshold. Most consensus scopes
of our clusters remain identical when the threshold varies
between 30% and 90%. The same property was observed
Network of metabolic drug scopes in the human irreversible case Figure 8
Network of metabolic drug scopes in the human irreversible case. Nodes of same color belong to the same k-core, 
isolated nodes are not shown. Groups of drugs belonging to the same therapy class are highlighted. Similar patterns were 
observed in the human reversible case.BMC Chemical Biology 2009, 9:4 http://www.biomedcentral.com/1472-6769/9/4
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with consensus scopes of clusters of individual com-
pounds [21].
Therapeutic properties
The DrugBank database also contains information about
the therapeutic properties and applications of each drug.
This information follows the Anatomic Therapeutic
Chemical (ATC) classification. The ATC system is used by
the World Health Organization as an international stand-
ard for drug utilization studies. It divides drugs into differ-
ent groups according to the organ or system on which they
act and their chemical, pharmacological and therapeutic
properties. Drugs are classified into groups at five different
levels. The first level of the code consists in a letter for the
anatomical group, there are 14 such groups.
The statistical significance of the enrichment of particular
therapeutic classes in clusters was tested by standard chi-
square tests. The null hypothesis is that the distribution of
any therapy in a cluster is not different from that of the
whole set of drugs. The associated p-values are indicated in
Results.
Scope network construction
Using the Jaccard distance as a measure of dissimilarity
between scopes, we constructed a similarity network com-
posed of scopes as nodes. Two scopes were connected by
an edge if the Jaccard distance between them was higher
than a given threshold. Drugs whose distance to any other
drug never exceeded the threshold, which would thus con-
stitute isolated nodes, were not included in the network
representation.
k-cores
Let G = (V, E) be a graph where V is the set of nodes and E
is the set of edges. A subgraph H = (W, E|W) induced by
the set W is a k-core iff ∀v ∈ W, deg(v) > k and H is a max-
imum subgraph with this property [28,29]. Given a graph
G, the algorithm of Batagelj & Zaversnik determines cores
hierarchy by recursively deleting all nodes and connected
edges of degree less than k. As a result, the remaining
graph is the k-core graph.
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